---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-061113"
form_type: "8-K"
ticker: "OTLK"
cik: "0001649989"
company_name: "Outlook Therapeutics, Inc."
filed_at: "2023-05-16T23:59:59+00:00"
generated_at: "2026-06-14T23:46:59.310007+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Outlook Therapeutics enters $100M ATM sales agreement with BTIG, terminates prior $40M ATM

## Summary
- ATM sales agreement with BTIG, LLC authorizes up to $100M in common stock sales at the market.
- Prior ATM with H.C. Wainwright & Co. for up to $40M terminated effective May 15, 2023.
- BTIG will receive a 3% commission on gross proceeds; sales may occur on Nasdaq or in private transactions.
- Company is not obligated to sell any shares; placement notices govern specific sales.
- Registration statement on Form S-3 (File No. 333-254778) effective April 1, 2021 covers the offering.

## SEC filing metadata
- accession: 0001104659-23-061113
- form_type: 8-K
- ticker: OTLK
- cik: 0001649989
- company_name: Outlook Therapeutics, Inc.
- filed_at: 2023-05-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 1.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649989/000110465923061113/0001104659-23-061113-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649989/000110465923061113/tm2315915d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-061113
- JSON: https://secwatch.observer/filing/0001104659-23-061113.json
- Plain text: https://secwatch.observer/filing/0001104659-23-061113.txt

## Key facts
- Material Agreements
  Outlook Therapeutics, Inc. entered into Sales Agreement with BTIG, LLC valued at aggregate offering price of up to $100,000,000 (effective 2023-05-16).
  - Action: entry
  - Agreement: atm program
  - Counterparty: BTIG, LLC
  - Value: aggregate offering price of up to $100,000,000
  - Effective: 2023-05-16
  source text: On May 16, 2023, Outlook Therapeutics, Inc. (the “Company”) entered into an at-the-market-sales agreement (the “Sales Agreement”) with BTIG, LLC (“BTIG”), pursuant to which the Company may issue and sell shares of its common stock, $0.01 par value per share (“Common Stock”), from time to time through BTIG as sales agent and/or principal having an aggregate offering price of up to $100,000,000 (the “Shares”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1649989/000110465923061113/0001104659-23-061113-index.htm
- Material Agreements
  Outlook Therapeutics, Inc. terminated Prior Sales Agreement with H.C. Wainwright & Co. valued at at-the-market offering agreement dated as of March 26, 2021, with aggregate offering price of up to (effective 2023-05-15).
  - Action: termination
  - Agreement: atm program
  - Counterparty: H.C. Wainwright & Co.
  - Value: at-the-market offering agreement dated as of March 26, 2021, with aggregate offering price of up to
  - Effective: 2023-05-15
  source text: In connection with entering into the Sales Agreement, the Company terminated, effective May 15, 2023, its at-the-market offering agreement, dated as of March 26, 2021 (the “Prior Sales Agreement”) with H.C. Wainwright & Co. with respect to an at-the-market offering program under which the Company could offer and sell, from time to time at its sole discretion, shares of its Common Stock having an aggregate offering price of up to $40,000,000 (the “Prior ATM Program”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1649989/000110465923061113/0001104659-23-061113-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.